All In Biotech

Drug Trial Radar · NCT02517021

A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting

A Phase 3, Multicenter, Randomized, Double-blind, Active Control Study to Evaluate the Safety and Efficacy of IV Pro-netupitant/Palonosetron (260 mg/0.25 mg) Combination for the Prevention of Chemotherapy-induced Nausea and Vomiting in Repeated Chemotherapy Cycles in Patients Receiving Highly Emetogenic Chemotherapy

Last checked: Nov 20, 2026Latest source record: Jun 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 405 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

405

Actual

Start

Nov 2015

Primary completion

Aug 2016

Study completion Aug 2016

Sponsor

Lead sponsor
Helsinn Healthcare SAIndustry
Sponsor type
Industry
Collaborators
PSI CRO
First posted
Aug 6, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

NEPA-15-18 is a clinical study assessing safety of pro-netupitant and palonosetron, two antiemetic drugs, given with oral dexamethasone. The objective of the study is to evaluate if pro-netupitant and palonosetron are safe when administered to prevent nausea and vomiting after administration of repeated cycles of chemotherapy.

Conditions

  • Chemotherapy-Induced Nausea and Vomiting

Interventions

  • Pro-netupitant/PalonosetronDrug

  • Netupitant/PalonosetronDrug

  • DexamethasoneDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Patients With Adverse EventsTime frame: Participants will be followed for the duration of the chemotherapy, an expected average duration of up to 14 weeks assuming a maximum of 4 chemotherapy cycles given every 3 weeks.

Locations

74 sites in 12 countries. Site status is shown where the registry gives one.

  • Sarcoma Oncology Center

    Santa Monica, California

  • The Oncology Institute of Hope and Innovation

    Whittier, California

  • St. Mary's Medical Center

    Grand Junction, Colorado

  • Well Pharma Medical Research Corporation

    Miami, Florida

  • Illinois CancerCare

    Peoria, Illinois

  • Indiana University Health Bloomington

    Bloomington, Indiana

  • Christus St. Frances Cabrini Hospital

    Alexandria, Louisiana

  • North Shore Hematology Oncology Associates PC

    East Setauket, New York

  • Gabrail Cancer Center Research

    Canton, Ohio

  • West Cancer Center

    Germantown, Tennessee

  • Provision Center for Biomedical Research

    Knoxville, Tennessee

  • University Hospital Graz, Department of Internal Medicine

    Graz, Austria

  • Krems Country Hospital

    Krems, Austria

  • Hospital Elisabethinen Linz GmbH, Internal Department #1 - Hemato-Oncology

    Linz, Austria

  • General Hospital Linz GmbH, Internal Medicine Department #3 - Center for Hematology and Medical Oncology

    Linz, Austria

  • University Hospital St. Poelten,1st Medical Department

    Sankt Pölten, Austria

  • Clinical Hospital Centre Osijek

    Osijek, Croatia

  • General Hospital Varazdin

    Varaždin, Croatia

  • Clinical Hospital Center "Sestre milosrdnice"

    Zagreb, Croatia

  • University Hospital Centre Zagreb "Jordanovac"

    Zagreb, Croatia

  • University Hospital Brno. Clinic of Pulmonary Diseases and Tuberculosis

    Brno, Czechia

  • University Hospital

    Brno, Czechia

  • Hospital Novy Jicin, Department of Oncology

    Nový Jičín, Czechia

  • Thomayer's Hospital, Clinic of Pneumology

    Prague, Czechia

  • Hospital Na Bulovce

    Prague, Czechia

  • Masaryk's Hospital Usti nad Labem, Oncology Dept

    Ústí nad Labem, Czechia

  • Onkoligische Schwerpunktpraxis Bielefeld

    Bielefeld, Germany

  • OncoResearch Lerchenfeld GmbH

    Hamburg, Germany

  • Hannover Medical School

    Hanover, Germany

  • Universitaetsklinikum Leipzig; Universitaeres Krebszentrum (UCCL)

    Leipzig, Germany

  • Staedtisches Klinikum Muenchen GmbH; Klinikum N euperlach

    München, Germany

  • Barziali Medical Center, Oncology Unit

    Ashkelon, Israel

  • Soroka University Medical Center,Oncology division

    Beersheba, Israel

  • Rambam Health Care Campus

    Haifa, Israel

  • S. G. Moscati Hospital, Medical Oncology Division

    Avellino, Italy

  • cientific Institute of Romagna for the Study and Treatment of Cancer (IRST), IRCCS

    Meldola, Italy

  • National Cancer Institute, IRCCS, Medical Oncology Department

    Milan, Italy

  • Azienda Socio Sanitaria Territoriale-Monza (ASST-Monza) - Oncology Department

    Monza, Italy

  • Regional Hospital "San Carlo"

    Potenza, Italy

  • Local Healthcare Company of Vimercate (ASST Vimercate)

    Vimercate, Italy

Showing 40 of 74 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.